Atrys Joins Europe’s Largest COMPASS Project to Advance Cancer-Related Cardiotoxicity Research
Atrys Health, a healthcare company specializing in oncology, telediagnostics, pathological anatomy, nuclear medicine, and precision medicine, has become a key participant in the COMPASS (Cardio Oncology Multidisciplinary Patient Assistance Solution) project, a landmark European research initiative dedicated to addressing one of the most pressing challenges in modern cancer care—cardiovascular complications caused by cancer therapies.
The ambitious multinational project represents the largest collaborative European effort focused on cancer-related cardiotoxicity, bringing together leading healthcare organizations, academic institutions, technology companies, patient advocacy groups, and clinical research centers to develop innovative solutions that improve the prevention, diagnosis, monitoring, and treatment of heart complications associated with cancer therapies.
Funded through the Innovative Health Initiative (IHI) with financial support from the European Union, the project has secured a budget exceeding €50 million and unites 62 organizations from 25 countries, creating an unprecedented network of expertise aimed at transforming cardio-oncology across Europe.
Addressing a Growing Challenge in Cancer Care
Over the past two decades, remarkable advances in oncology have significantly improved survival rates for many forms of cancer. Breakthrough therapies, including targeted treatments, immunotherapies, and advanced chemotherapy regimens, have enabled patients to live longer and enjoy improved quality of life.
However, these advances have also brought increasing attention to an important long-term consequence of cancer treatment—cardiotoxicity, or damage to the cardiovascular system caused by cancer therapies.
Many commonly used cancer treatments can adversely affect the heart and blood vessels, leading to conditions such as heart failure, arrhythmias, hypertension, coronary artery disease, and reduced cardiac function. In some patients, these complications develop during treatment, while others may experience cardiovascular problems months or even years after completing therapy.
As cancer survival continues to improve, healthcare providers face the growing challenge of managing these delayed cardiovascular effects while ensuring patients continue to receive effective cancer treatment.
This emerging medical specialty, known as cardio-oncology, seeks to balance successful cancer treatment with cardiovascular protection by integrating expertise from oncology, cardiology, genetics, imaging, and digital health.
The COMPASS project has been established specifically to advance this multidisciplinary approach.
Europe’s Largest Cardio-Oncology Consortium
COMPASS represents one of the most extensive healthcare research collaborations ever launched in Europe within the field of cardio-oncology.
The consortium includes hospitals, universities, research institutes, medical technology companies, biotechnology organizations, small and medium-sized enterprises, and patient organizations working together toward shared objectives.
Academic coordination of the initiative is led by King’s College London, while industrial leadership is provided by GE HealthCare, combining scientific excellence with medical technology innovation.
The project will run over the next five years and aims to create a comprehensive ecosystem capable of improving cardiovascular care throughout every stage of a patient’s cancer journey.
Rather than relying on isolated clinical assessments, COMPASS intends to integrate diverse sources of medical information—including genetic data, biomarkers, imaging results, clinical records, wearable technologies, and artificial intelligence—to enable clinicians to make more informed and personalized treatment decisions.
The ultimate goal is to reduce treatment-related cardiovascular complications while allowing patients to continue receiving the most effective cancer therapies safely.
Atrys Brings Expertise in Precision Medicine
Within the multinational consortium, Atrys will contribute its extensive capabilities in clinical genomics, pharmacogenomics, and personalized medicine.
These disciplines are becoming increasingly important in identifying patients who may be genetically predisposed to developing cardiovascular complications from specific cancer treatments.
Clinical genomics examines genetic variations that influence disease risk and treatment response, while pharmacogenomics studies how an individual’s genetic profile affects the way medications are metabolized and tolerated.
By combining these approaches, researchers can potentially identify patients who are more susceptible to cardiotoxicity before treatment even begins.
Atrys will support the development of predictive models capable of estimating cardiovascular risk in cancer patients using advanced genomic and clinical information.
These predictive tools could allow physicians to tailor treatment plans according to each patient’s individual risk profile, improving both cancer outcomes and cardiovascular safety.
Instead of applying identical monitoring strategies to all patients, clinicians could provide enhanced surveillance for higher-risk individuals while reducing unnecessary testing for those with lower risk.
Such personalized care represents one of the central objectives of precision medicine.
Building Predictive Models Through Data Integration
A major component of Atrys’ involvement focuses on integrating multiple forms of medical data into advanced predictive algorithms.
The company will participate in activities involving:
- Clinical information
- Genetic and genomic data
- Pharmacogenomic profiles
- Biomarkers
- Advanced cardiac imaging
- Digital health technologies
- Artificial intelligence-driven analytics
Combining these datasets may enable researchers to detect subtle warning signs of cardiovascular injury much earlier than conventional clinical methods.
Artificial intelligence systems can identify complex patterns across millions of data points that would be impossible for clinicians to analyze manually.
Researchers hope these models will provide physicians with practical clinical decision-support tools capable of predicting which patients require closer monitoring or modified treatment strategies.
Artificial Intelligence at the Center of Future Care
Artificial intelligence will play a central role throughout the COMPASS initiative.
Machine learning technologies have demonstrated growing potential across healthcare by identifying hidden relationships within large clinical datasets.
In cardio-oncology, AI may help clinicians predict adverse cardiac events, interpret imaging studies more efficiently, recognize biomarker patterns associated with early heart damage, and generate individualized patient risk assessments.
Rather than replacing physicians, these AI-powered systems are intended to support clinical decision-making by providing additional insights based on continuously updated patient information.
The COMPASS project aims to ensure these technologies are practical, clinically validated, and suitable for routine healthcare settings across Europe.
Enhancing Collaboration Between Oncology and Cardiology
One of the longstanding challenges in cancer care has been ensuring seamless communication between oncologists and cardiologists.
Cancer specialists naturally prioritize effective tumor control, while cardiologists focus on preserving cardiovascular health.
Patients experiencing treatment-related heart complications often require coordinated management involving both specialties.
COMPASS seeks to improve this collaboration by developing integrated clinical pathways and digital tools that allow healthcare professionals from different disciplines to share patient information more effectively.
This multidisciplinary approach aims to reduce fragmented care while improving treatment decisions throughout the patient’s healthcare journey.
Atrys will contribute to evaluating not only the scientific aspects of these solutions but also their practical implementation in real-world healthcare systems.
Evaluating Clinical Feasibility and Sustainability
Beyond developing innovative technologies, the consortium recognizes that successful healthcare innovation requires practical implementation.
Many promising medical technologies fail to reach routine clinical practice because they are difficult to integrate into existing hospital workflows or healthcare systems.
Atrys will therefore participate in assessing the feasibility, sustainability, and real-world applicability of the project’s solutions.
Researchers will evaluate whether newly developed predictive models, digital platforms, and clinical decision-support systems can be effectively adopted across diverse healthcare environments.
This implementation-focused approach increases the likelihood that COMPASS outcomes will extend beyond research publications and generate tangible improvements in patient care.
Leadership Perspective
According to José Antonio López Martín, Head of Research and Innovation at Atrys, participation in COMPASS aligns closely with the company’s long-term strategy of advancing personalized healthcare.
He emphasized that clinical genomics and precision medicine can play a critical role in anticipating cardiovascular complications associated with cancer treatment before they become clinically significant.
He noted that Atrys aims to contribute to one of oncology’s major healthcare challenges by helping translate scientific discoveries into practical clinical tools that healthcare professionals can use during everyday patient care.
Ultimately, the objective is to improve clinical decision-making while delivering increasingly personalized treatment strategies for cancer patients.
Transforming the Future of Cardio-Oncology
The growing burden of cancer-related cardiotoxicity has created an urgent need for more sophisticated methods of patient monitoring and risk assessment.
As cancer therapies continue to evolve, clinicians require equally advanced tools capable of balancing treatment effectiveness with long-term cardiovascular protection.
COMPASS represents an important step toward achieving this balance.
By integrating genomics, biomarkers, imaging technologies, artificial intelligence, wearable devices, and multidisciplinary clinical expertise, the project seeks to create a comprehensive patient assistance solution capable of supporting clinicians throughout every phase of cancer treatment.
Researchers anticipate that these innovations will enable earlier detection of cardiovascular injury, more accurate prediction of patient risk, improved treatment personalization, and stronger collaboration among healthcare professionals.
Reinforcing Atrys’ Commitment to Healthcare Innovation
Participation in COMPASS further strengthens Atrys’ position as an innovator in precision medicine and digital healthcare.
The company’s expertise across oncology, molecular diagnostics, genomics, pathology, telemedicine, and nuclear medicine places it in a strong position to contribute to multidisciplinary research initiatives addressing complex healthcare challenges.
Through this collaboration, Atrys continues expanding its role in developing clinical solutions that combine advanced diagnostics with personalized treatment strategies.
The project also reflects the company’s broader commitment to improving patient outcomes through research-driven innovation while supporting the evolution of precision medicine across Europe.
As COMPASS progresses over the next five years, Atrys and its consortium partners hope their collective work will establish new standards for predicting, preventing, and managing cardiovascular complications in cancer patients.
If successful, the initiative could help transform cardio-oncology by enabling more proactive, personalized, and integrated care—ultimately improving both survival and quality of life for thousands of cancer patients across Europe and beyond.
Source link: https://www.atryshealth.com/
